Trial Profile
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Conestat alfa (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms PROTECT
- 17 Oct 2018 Primary endpoint has been met. (Peak change from baseline of urinary Neutrophil gelatinase-associated lipocalin), according to a Pharming Group NV media release.
- 17 Oct 2018 Results presented in the Pharming Group NV media release.
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.